Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Xarelto (rivaroxaban)
pCPA File Number:
20785
Negotiation Status:
Concluded with an LOI
Indication(s):
Atrial fibrillation, stroke prevention
Sponsor/Manufacturer:
Bayer Inc.
CADTH Project Number:
S0257
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
2012-06-19